ArticleOncology letters2026
Single-cell transcriptomics identifies PRDX1 and GPX4 as potential ferroptosis regulators and tumor microenvironment--related molecules in hepatocellular carcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the expression and roles of peroxiredoxin 1 (PRDX1) and glutathione (GSH) peroxidase 4 (GPX4) in ferroptosis regulation and the tumor microenvironment in hepatocellular carcinoma (HCC). The expression levels of PRDX1 and GPX4 were assessed in HCC through analysis of datasets from The Cancer Genome Atlas (TCGA), GSE14520 from the Gene Expression Omnibus database and the Human Protein Atlas, along with HCC cell lines. Diagnostic and prognostic values were evaluated using receiver operating characteristic curves and Kaplan-Meier survival analyses. The single-cell dataset GSE149614 was employed to investigate the cellular localization and characteristics of specific cell subpopulations expressing PRDX1 or GPX4 within the HCC tumor microenvironment. The relationships between PRDX1, GPX4 and ferroptosis-related pathways were explored using the FerrDb database and Gene Set Enrichment Analysis. Additionally, their interactions with the immune microenvironment were examined utilizing the CIBERSORT algorithm. To validate the results of the bioinformatics analysis, the present study utilized small interfering (si)RNA technology to construct single gene knockdown and dual gene co-knockdown models targeting PRDX1 and GPX4 in Hep3B cells. Subsequently, the proliferative activity of each group of cells was evaluated using the Cell Counting Kit-8 method and the levels of the intracellular lipid peroxidation product malondialdehyde (MDA) were detected using the MDA detection kit. The results of the present study demonstrated that the expression levels of PRDX1 and GPX4 were upregulated in HCC tissues and cell lines. The area under the curve for the combined diagnostic model of PRDX1 and GPX4 in HCC was 0.83. Furthermore, elevated expression levels of PRDX1 or GPX4 predicted reduced overall survival (OS), and their expression was weakly positively correlated in HCC. Single-cell transcriptomics demonstrated predominant expression of both genes in malignant cells. GPX4 was primarily detected in early-differentiation subgroups enriched in metabolic and ferroptosis pathways, whereas PRDX1 was predominantly expressed in intermediate-differentiation subgroups associated with antioxidative stress pathways. The dual-high PRDX1/GPX4 expression group exhibited increased reactive oxygen species, GSH and iron levels, whereas the dual-low group had prolonged OS. Immune infiltration analysis indicated a trend of higher M0 macrophage levels and lower CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.